CBFB-MYH11 RQ Kit

A reagent kit for detection and quantification of mRNAs produced by chimeric CBFB-MYH11 gene and reference ABL gene in clinical material by polymerase chain reaction (PCR) with real-time hybridization-fluorescence detection.
The reagent kit can be used to reveal AML associated with CBFB-MYH11 chromosomal rearrangement, to confirm the AML diagnosis, and to monitor the efficiency of therapy, i.e., MRD evaluation.
The reagent kit is designed to conduct a study in a quantitative format for 24 clinical samples in duplicate (132 PCR reactions, including controls).

Additional information about the molecular marker
Chromosome 16 inversion inv(16)(p13q22) occurs in about 8-9% of primary acute myeloid leukemia (AML), and results in fusion of the CBFb gene, which encodes part of the CBF transcription factor and MYH11 gene encoding the heavy chain of myosin smooth muscle fibers. A total of 10 transcript variants of the CBFB-MYH11 gene were found: transcript A is detected in more than 85% of inv(16)-positive patients, types D and E are detected in about 5% of patients, the remaining variants occur rarely (Figure 1).

 

Figure 1. Arrangement of CBFB-MYH11 A, D, and E chimeric transcripts. Binding sites for primers and probes for real-time PCR are marked. The positions of primers and probes are indicated relative to the 5' end of the nucleotide sequences of normal transcripts.

AML patients with chromosome 16 inversion usually have a favorable prognosis, with more than 50% of patients achieving complete remission. Accordingly, CBFB-MYH11 translocation is an important target in the diagnosis and monitoring of minimal residual disease (MRD). When compared with standard methods (karyotyping, FISH), usage of real-time PCR (Real-Time Quantitative PCR, RQ-PCR) which measures CBFB-MYH11 expression levels provides significantly higher sensitivity when assessing minimal residual disease (MRD), revealing one malignant cell among 50,000 normal ones.
More detailed information on diagnostic approaches, frequency of the study and prognostic value of this testing in leukemias are available on the website of the International Network European Leukemia Net (http://www.leukemia-net.org).

Ordering information:

CBFB-MYH11 A RQ Kit, 24 tests                                                                                     Cat.No IG-RQ-3-24
CBFB-MYH11 D RQ Kit, 24 tests                                                                                    Cat.No IG-RQ-4-24

Additiional reagents:

Blood RNA stabilizer medium                                                                                         Cat.No IG-RSB-100
TriZ Reagent Kit                                                                                                              Cat.No IG-TRK-100
ReverZyme Kit                                                                                                                Cat.No IG-RT-1
Erythrocyte Lysis Solution                                                                                               Cat.No IG-TRL-100

Price: on request 

Reagents are for research use only (RUO)


Back to HemaPrime products

© Inogene LLC 2022